DEC 23, 2008
ViRexx Medical Corp. Is Acquired by Paladin Labs Inc.

DEC 11, 2008
Notice to Shareholders Regarding the Results of a Court Application For an Order for Reorganization of ViRexx Medical Corp. and to Approve Proposal

DEC 2, 2008
Notice to Shareholders Regarding a Court Application for an Order for Reorganization of ViRexx Medical Corp.

NOV 21, 2008
ViRexx Announces Appointment of Directors and Notice of Intention to Make a Proposal to Creditors

SEP 19, 2008
ViRexx Announces LM Funds Corp. Excercises Option to Exchange Convertible Loan

SEP 15, 2008
ViRexx Announces Failure to Secure an Alternative Equivalent Funder to Replace LM Funds Corp.

SEP 10, 2008
ViRexx Announces Results of Rights Offering and Failure of LM Funds Corp. to Provide Standby Commitment

AUG 28, 2008
ViRexx Receives Delisting Notification From AMEX Regarding Non-Compliance With Listing Standards

AUG 18, 2008
ViRexx Announces Encouraging Results From Its Lead Chimigen(TM) Therapeutic Vaccine Candidate for Treating Chronic Hepatitis B Virus Infections

AUG 14, 2008
ViRexx Announces 2008 Second Quarter Results

AUG 1, 2008
ViRexx Announces Approvals of Rights Offering

JUL 16, 2008
ViRexx Announces Record Date for Rights Offering

JUL 10, 2008
ViRexx Announces Filing of Amended and Restated Audited Financial Statements for Year Ended December 31, 2007 and Amended and Restated Annual Report on Form 20-F

JUN 5, 2008
ViRexx Announces $1,000,000 Financing and Standby Purchaser for Rights Offering to Shareholders

MAY 13, 2008
ViRexx Announces 2008 First Quarter Results and Receives Notification of Non-Compliance From the American Stock Exchange

APR 8, 2008
ViRexx Announces Change in Board

MAR 31, 2008
ViRexx Announces Rights Offering to Shareholders

FEB 12, 2008
ViRexx Announces 2007 Fiscal Year Results

DEC 5, 2007
ViRexx Announces Pivotal OvaRex(R) MAb Trial Results Fail to Achieve Statistical Significance

NOV 15, 2007
CORRECTION FROM SOURCE: ViRexx Announces Third Quarter Results

NOV 14, 2007
ViRexx Announces Third Quarter Results

OCT 17, 2007
ViRexx Announces Reconciliation With Sigma Tau

OCT 16, 2007
ViRexx Announces Second OvaRex(R) MAb Phase III Trial Reaches 118th Relapse Event

OCT 12, 2007
ViRexx Announces Appointment of COO

SEP 21, 2007
ViRexx Announces Change in Officer

SEP 7, 2007
ViRexx Reviews Corporate Governance

SEP 5, 2007
ViRexx Announces Voluntary Trading Halt

AUG 14, 2007
ViRexx Announces Second Quarter Results

JUL 25, 2007
ViRexx Management Wishes to Provide a Corporate Update

JUN 8, 2007
ViRexx Licensing Partner Presents OvaRex(R) MAb Phase II Trial Results at ASCO

MAY 30, 2007
ViRexx Announces Collaboration With the National Institute of Nanotechnology (NINT) and Defence Research and Development Canada Suffield (DRDC Suffield) With Networking and Financial Contribution

MAY 16, 2007
ViRexx Medical Corp.: Letter to Shareholder

MAY 14, 2007
ViRexx Announces First Quarter Results

MAY 7, 2007
ViRexx Announces Appointment of Directors and Interim Chief Executive Officer and Formation of Special Committee

MAY 3, 2007
ViRexx Announces Change in Management and Board of Directors

APR 9, 2007
ViRexx Announces Change in Board and Termination of Public Financing

MAR 23, 2007
ViRexx Announces 2006 Fiscal Year Results

FEB 16, 2007
ViRexx Announces Change in Board and 13D Filing

JAN 29, 2007
ViRexx Files Preliminary Short Form Prospectus for up to $15 Million Offering

NOV 28, 2006
ViRexx Interviewed by the Zangani Investor Community

NOV 28, 2006
ViRexx to Focus on Near Term Potential Revenue Streams

NOV 15, 2006
ViRexx Founders Inducted Into the BioIndustry Hall of Fame

NOV 9, 2006
ViRexx Announces Third Quarter Results

NOV 6, 2006
ViRexx Announces Comprehensive Partnership for OvaRex'R' Mab

AUG 10, 2006
ViRexx Announces Second Quarter Results

AUG 9, 2006
ViRexx Completes Treatment in HepaVaxx B Vaccine Phase I Study

JUN 22, 2006
ViRexx Announces Completion of Enrollment for Phase III OvaRex'R' MAb Trials

JUN 19, 2006
ViRexx Presents at Rodman & Renshaw Third Annual Security, Biodefense, & Connectivity Investor Conference

JUN 15, 2006
ViRexx Announces the Initiation of a Phase I Clinical Study of HepaVaxx B

JUN 5, 2006
ViRexx Shareholders Elect Michael Marcus to Board of Directors

MAY 19, 2006
ViRexx to Present at SMi Third Biannual Vaccines Conference

MAY 15, 2006
ViRexx Announces First Quarter Results

MAY 8, 2006
ViRexx to Present at Rodman & Renshaw Third Annual Global Healthcare Conference

MAY 3, 2006
ViRexx to Present at BioFinance 2006

MAY 2, 2006
ViRexx Featured in Biotech Monthly

APR 28, 2006
ViRexx President Interviewed by the Zangani Investor Community

APR 27, 2006
ViRexx Receives Approval to Undertake HepaVaxx B Phase I Trial

APR 24, 2006
ViRexx Announces New Chief Financial Officer

APR 7, 2006
Virexx Completes $1,000,000 Private Placement

APR 6, 2006
ViRexx Retains Leading Defense Procurement Advocate

APR 5, 2006
ViRexx CEO, Dr. Lorne Tyrrell, to Present at the Management of Chronic Hepatitis B Virus 2006 Meeting

MAR 31, 2006
ViRexx Announces Collaboration with Defence Research and Development Canada-Suffield to Expand Chimigen'TM' Platform Technology for Use in Biodefense

MAR 24, 2006
ViRexx President Interviewed by the Zangani Investor Community

MAR 16, 2006
ViRexx Announces 2005 Fiscal Year Results

MAR 3, 2006
ViRexx Announces Private Placement

FEB 22, 2006
ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus & Insect Cell Culture Annual Meeting

FEB 16, 2006
ViRexx Completes $12 Million Private Placement

JAN 30, 2006
ViRexx Invited to Attend the Capitol Hill BioDefense Showcase

JAN 19, 2006
ViRexx Founders Receive BioAlberta Lifetime Achievement Award

DEC 30, 2005
ViRexx Acknowledges Contribution of Former Executive

DEC 23, 2005
ViRexx to List on the American Stock Exchange

DEC 14, 2005
ViRexx Announces Enrollment Completion of Ovarex'R' MAb Phase III Trial for Ovarian Cancer

DEC 12, 2005
ViRexx to Present Hepatitis C Vaccine Data at HepDART 2005

DEC 8, 2005
ViRexx Files CTA for Hepaptitis B Therapeutic Vaccine

DEC 6, 2005
ViRexx Founder Antoine Noujaim Honoured with Centennial Medal

NOV 16, 2005
ViRexx Announces Postive Interim Results for Occlusin'TM' 50 Injection

NOV 15, 2005
ViRexx to Present at Technology Finance 2005

NOV 14, 2005
ViRexx Announces Third Quarter Results

NOV 10, 2005
ViRexx Receives U.S. Patent for Occlusin'TM' Embolotherapy

NOV 3, 2005
ViRexx Announces Management Change

NOV 3, 2005
ViRexx To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference

OCT 24, 2005
ViRexx Appoints Dr. Lorne Tyrrell Chief Executive Officer

OCT 3, 2005
ViRexx To Present Data On Chimigen'TM' Vaccine At 12th International Symposium On Hepatitis C And Related Viruses

SEP 30, 2005
Dr. Lorne Tyrrell of ViRexx Wins Prestigious EnCana Principal Award

SEP 12, 2005
ViRexx Completes $4 Million Private Placement

AUG 15, 2005
Virexx Announces Second Quarter Results

AUG 15, 2005
Virexx Announces Restatement of First Quarter Financial Statements

JUN 28, 2005
ViRexx Announces Transfer Of Warrants

JUN 16, 2005
ViRexx Announces Extension of Warrants

JUN 16, 2005
ViRexx to Present at Bio 2005

JUN 9, 2005
ViRexx Provides Affirmation of Clinical Progress and Anticipated Milestones; Further Solidifies Patent Position

MAY 11, 2005
ViRexx Announces First Quarter Results

APR 28, 2005
ViRexx Announces Manufacturing and Supply Agreement with Protein Sciences Corporation for HepaVaxx B Vaccine

APR 26, 2005
ViRexx Receives U.S. Patent For Immunotherapeutic Compound ProstaRex

APR 20, 2005
ViRexx Partner Presents at Annual Conference of The American Association of Cancer Research

MAR 22, 2005
ViRexx Reports 2004 Results and Provides Update

JAN 12, 2005
ViRexx Appoints President and Chief Operating Officer

DEC 21, 2004
ViRexx Announces Normal Course Issuer Bid

DEC 13, 2004
ViRexx Reports on Acquisition of AltaRex

DEC 1, 2004
ViRexx & AltaRex Announce National Merit Award For Founder

OCT 29, 2004
ViRexx Provides Update and Reports Financial Results for Third Quarter

OCT 15, 2004
AltaRex And ViRexx Announce Transaction

OCT 6, 2004
ViRexx to Present at International Symposium on HCV

SEP 29, 2004
ViRexx Recipient of ASTech Award

SEP 23, 2004
ViRexx Receives Approval for Phase I Clinical Trial

AUG 26, 2004
ViRexx Files Occlusin'TM' Injection CTA With Health Canada

AUG 18, 2004
ViRexx CSO Awarded Top Medical Honour

AUG 13, 2004
ViRexx Announces Results for Second Quarter of 2004

JUN 23, 2004
ViRexx Receives Notice of Allowance for Patents Protecting Novel Tumor Starvation Technology

JUN 18, 2004
ViRexx Receives Notice of Allowance for a U.S. Patent Protecting T-ACT'TM' Technology

JUN 1, 2004
ViRexx Announces Lifetime Achievement Award for Founder

MAY 26, 2004
ViRexx Announces Financial Results For First Quarter Of 2004

MAY 20, 2004
ViRexx Presents Pre-Clinical Safety and Efficacy Results at Vascular Targeting Conference

MAY 17, 2004
ViRexx to Present at International Vascular Targeting Conference

MAY 6, 2004
ViRexx Provides Operational Update and Reports 2003 Financial Results

APR 26, 2004
ViRexx Receives $500,000 Commercialization Award from Alberta Heritage Foundation for Medical Research

APR 15, 2004
ViRexx Appoints Directors And Vice President, Drug Development; Company Also Appoints Corporate Consultant and Investor Relations Consultant for US and Europe

APR 15, 2004
ViRexx Completes Public Offering and Exercise of Over Allotment Option

MAR 30, 2004
ViRexx Medical Corp. Retains The Equicom Group Inc. as Investor Relations Advisor

JAN 7, 2004
ViRexx Medical Corp.: Press Release